Treatment of borderline personality disorder: Potential of the new antipsychotic medications

Journal of Practical Psychiatry and Behavioral Health

Volumn 5, Issue 5, 1999, Pages 247-255

  Schulz, S Charles ^a   Camlin, Kelly L ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Atypical antipsychotics; Borderline personality disorder; Clozapine; Low dose neuroleptic strategy; Olanzapine; Quetiapine; Risperidone; Traditional antipsychotics

Indexed keywords

EID: 0001642445     PISSN: 10765417     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Kane J, Hongfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenia: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
2. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
3. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-23.
4. Arvanitis LA, Miller BG, and the Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-46.
5. Tollefson GD, Sanger TM, Lu Y, Thieme ME. Depressive signs and symptoms in schizophrenia: A prospective blinded trail of olanzapine and haloperidol. Arch Gen Psychiatry 1998;55:250-8.
6. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials. J Clin Psychiatry 1997;58:538-46.
7. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10:779-812.
8. Calabrese JR, Kimmel SE, Woyshville MJ, et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996;153:759-64.
9. Ranjan R, Meltzer HY. Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression. Biol Psychiatry 1996;40:253-8.
10. Tollefson GD, Shelton R, Mauricio T, et al. The study of olanzapine combined with fluoxetine in patients with treatment-resistant major depressive disorder without psychotic features. American College of Neuropsychopharmacology 37th Annual Meeting, December 14-18, 1998.
11. Volavka J, Zito JM, Vitrai J, Czobar P. Clozapine effects on hostility and aggression in schizophrenia. J Clin Psychopharmacol 1993;13:287-9.
12. Buckley P, Bartell J, Donenwirth K, Lee S, Torigoe F, Schulz SC. Violence and schizophrenia: Clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law 1995;23:607-11.
13. Brecher M, Jeste D, Okamoto A, Napolitano J, Kane JM. Low frequency for tardive dyskinesia in elderly patients with dementia exposed to risperidone for up to one year. Am College of Neuropsychopharmacology 37th Annual Meeting, December 14-18, 1998.
14. Findling R, McNamara NK, Branicky LA, et al. Conduct disorder in children treated with risperidone. American College of Neuropsychopharmacology 37th Annual Meeting, December 14-18, 1998.
15. Kemph JP, Devane CL, Levin GM, Jarecke R, Miller RL. Treatment of aggressive children with clonidine: Results of an open pilot study. J Am Acad Child Adolesc Psychiatry 1993;32:577-81.
16. Davis JM, Janicak PG. Risperidone: A new, novel (and better?) antipsychotic. Psychiatric Annals 1996;26:78-87.
17. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.
18. Mack JE: Borderline states: An historical perspective. In: Mack JE, ed. Borderline states in psychiatry. New York: Grune & Stratton; 1975: 1-27.
19. Hoch P, Polatin P. The diagnosis of pseudoneurotic schizophrenia. Psychiatry Q 1949;23:248-76.
20. Knight R. Borderline states. Bull Menninger Clin 1953;17:1-12.
21. Kety SS, Rosenthal D, Wender PH, Schulsinger F, Jacobsen B. Mental illness in the biological and adoptive families of adoptive individuals who have become schizophrenic: A preliminary report based on psychiatric interviews. In: Fieve RR, Rosenthal D, Brill H, eds. Genetic research in psychiatry. Baltimore: Johns Hopkins University Press; 1975: 147-65.
22. Gunderson JG. The relatedness of borderline and schizophrenic disorders. Schizophr Bull 1979;5:17-22.
23. Gunderson JG, Singer MT. Defining borderline patients: An overview. Am J Psychiatry 1975;132:1.
24. Gunderson JG, Kolb JE, Austin V. The diagnostic interview for borderline patients. Am J Psychiatry 1981;138:896-903.
25. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd Edition. Washington, DC: American Psychiatric Association; 1980.
26. Spitzer R, Endicott J, Gibbon M. Crossing the borderline into borderline personality and borderline schizophrenia. Arch Gen Psychiatry 1979;36:17-24.
27. Kernberg O. Borderline personality organization. J Am Psychoanal Assoc 1967;15:641-85.
28. Cloninger CR. A systematic method for clinical description and classification of personality variants. Arch Gen Psychiatry 1987;44:573-88.
29. Schulz SC, Goldberg SC. Is borderline personality an illness? Psychopharmacol Bull 1984;20:554-60.
30. Robins E, Guze S. Establishment of diagnostic validity in psychiatric illness: Its application to schizophrenia. Am J Psychiatry 1970;126:983-7.
31. Klein DF. Psychiatric diagnosis and typology of clinical drug effects. Psychopharmacology 1968;13:359-86.
32. Hedberg DC, Hauch JH, Glueck BC. Tranylcypromine-trifluoperazine combination in the treatment of schizophrenia. Am J Psychiatry 1971;127:1141-6.
33. Brinkley JR, Beitman BD, Friedel RO. Low-dose neuroleptic regimens in the treatment of borderline patients. Arch Gen Psychiatry 1979;36:319-26.
34. Leone NF. Response of borderline patients to loxapine and chlorpromazine. J Clin Psychiatry 1982;43:148-50.
35. Serban G, Seigel S. Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. Am J Psychiatry 1984;141:1455-8.
36. Goldberg SC, Schulz SC, Schulz PM, Resnick RJ, Hamer RM, Friedel RO. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs. placebo. Arch Gen Psychiatry 1986;43:680-6.
37. Soloff PH, George A, Nathan RS, Schulz PM, Ulrich RF, Perel J. Progress in pharmacotherapy of borderline disorders. Arch Gen Psychiatry 1986;43:691-7.
38. Endicott J, Spitzer RL, Fleiss JL, et al. The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766-71.
39. Derogatis LR, Lipman RS, Covi L. SCL-90: An outpatient psychiatric rating scale: Preliminary report. Psychopharmacol Bull 1973;9:13-28.
40. Hymowitz P, Frances A, Jacobsberg LB, Sickles M, Hoyt R. Neuroleptic treatment of schizotypal personality disorders. Compr Psychiatry 1986;27:267-75.
41. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder: Alprazolam, carbamazepine, trifluoperazine and tranylcypromine. Arch Gen Psychiatry 1988;45:111-9.
42. Soloff PH, Cornelius J, George A, Nathan S, Perel JM, Ulrich RF. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 1993;50:377-85.
43. Cornelius JR, Soloff PH, Perel JM, Ulrich RF. A preliminary trial of fluoxetine in refractory borderline patients. J Clin Psychopharmacol 1991;11:116-20.
44. Markovitz PJ, Calabrese JR, Schulz SC, Meltzer HY. Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry 1991;148:1064-7.
45. Norden MJ. Fluoxetine in borderline personality disorder. Progr Neuro-Psychopharmacol Biol Psychiatry 1989;13:885-93.
46. Salzman C, Wolfson AN, Schatzberg A, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995;15:23-9.
47. Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 1997;54:1801-8.
48. Teicher MH, Glod CA, Aaronson ST, Gunter PA, Schatzberg AF, Cole JO. Open assessment of the safety and efficacy of thioridazine in the treatment of patients with borderline personality disorder. Psychopharmacol Bull 1989;25:535-49.
49. Kutcher S, Papatheodorou G, Reiter S, Gardner D. The successful pharmacological treatment of adolescents and young adults with borderline personality disorder: A preliminary open trial of flupenthixol. J Psychiatry Neurosci 1995;20:113-8.
50. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY. Improvement in cognitive functions and psychiatric symptoms in treatment: Refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993;34:702-12.
51. Green MF, Marshall BD Jr, Wirshing WC, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997;154:799-804.
52. O'Leary KM, Cowdry RW. Neuropsychological testing results in borderline personality disorder. In: Silk KR, ed. Biological and neurobehavioral studies of borderline personality disorder. Washington, DC: American Psychiatric Press; 1994: 109-25.
53. Tohen M, Jacobs T, Cannon KS, et al. Antimanic effect and cognitive improvement in bipolar I patients treated with olanzapine. American College of Neuropsychopharmacology 37th Annual Meeting, December 14-18, 1998, page 305.
54. Roth BL, Berry SA, Kroeze WK, Willins DL, Kristiansen K. Serotonin 5HT2A receptors: Molecular biology and mechanisms of regulation. Critical Reviews in Neurobiology 1998;12:319-38.
55. Frankenburg FR, Zanarini MC. Clozapine treatment of borderline patients: A preliminary study. Compr Psychiatry 1993;34:402-5.
56. Benedetti F, Sforzini L, Colombo C, Maffei C, Smeraldi E. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 1998;59:103-7.
57. Szigethy EM, Schulz SC. Risperidone in co-morbid borderline personality disorder and dysthymia. J Clin Psychopharmacol 1997;17:326-7.
58. Kujawa MJ, Berry SA, Camlin KL, Schulz SC. Atypical antipsychotic treatment of BPD. American Psychiatric Association, Annual Meeting, May 30-June 4, 1998, page 89.
59. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd Edition, Revised. Washington, DC: American Psychiatric Association; 1987:12.
60. Schulz SC, Camlin KL, Berry S, Friedman L. Risperidone for borderline personality disorder: A double-blind study. American College of Neuropsychopharmacology, 37th Annual Meeting, December 14-18, 1998, p. 252.
61. Spitzer RL, Williams JBW, Gibbon M, First MB. Structured clinical interview for DSM-III-R Axis II disorders (SCID-II). Washington, DC: American Psychiatric Press; 1990.
62. Barratt EL. Factor analysis of some psychometric measures of impulsiveness and anxiety. Psychol Rep 1965;16:547-54.
63. Baron M, Asnis L, Gruen R. Schedule of interviewing schizotypal personalities: A diagnostic interview for schizotypal features. Psychiatry Res 1981;4:213-28.
64. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212:11-9.
65. Siever LJ. Novel antipsychotics in personality disorders. American Psychiatric Association, Annual Meeting, May 30-June 4, 1998.
66. Camlin KL, Berry SA, Whyte EM, Jesberger JA, Schulz SC. Olanzapine safety and efficacy in patients with borderline personality disorder and co-morbid dysthymia. Schizophr Res 1999;36:273.
67. Buss AH, Durkee A. An inventory for assessing different kinds of hostility. J Consult Psychol 1957; 21:343-9.
68. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia: A high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997;54:549-57.
69. Schulz SC, Camlin KL, Hrouda D, Hagger C, Jesberger J. Quetiapine safety and efficacy in patients with borderline personality disorder. IRB approved protocol at Case Western Reserve University and University Hospitals of Cleveland, 1999.
70. Braff DL, Geyer MA. Sensorimotor gating and the neurobiology of schizophrenia: Human and animal model studies. In: Schulz SC, Tamminga CA. Schizophrenia: Scientific progress. New York: Oxford University Press; 1989: 124-36.
71. Swerdlow NR, Filion D, Geyer MA, Braff DL. "Normal" personality correlates of sensorimotor, cognitive, and visuospatial gating. Biol Psychiatry 1995;37:286-99.
72. Swerdlow NR, Bakshi V, Waiker M, Taaid N, Geyer MA. Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats. Psychopharmacology 1998;140:75-80.
73. Benjamin L, Li L, Patterson C, Greenberg B, Murphy D, Hamer D. Population and familial association between the D4 dopamine receptor and measures of novelty seeking. Nat Genet 1996;12:11-5.
74. Ebstein R, Novick O, Umansky R, et al. D4DR exon III polymorphism associated with the personality trait of novelty seeking in normal human volunteers. Nat Genet 1996;12:78-80.
75. Endicott J, Shea MT. Measurement of change in personality disorders. Psychopharmacol Bull 1989;25:572-77.76.
76. Linehan MM, Tutek DA, Hears HL, Armstrong HE. Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. Am J Psychiatry 1994;151:1771-6.